Immatics (IMTX) Change in Receivables (2019 - 2025)
Immatics recorded quarterly Change in Receivables of -$5.3 million in Q4 2025, down 254.73% quarter-over-quarter from -$1.5 million in Q3 2025, and down 870.14% year-over-year from $688175.4 in Q4 2024.
Immatics' Change in Receivables history runs 7 years deep, the most recent figure standing at -$5.3 million for Q4 2025.
- In Q4 2025, Change in Receivables fell 870.14% year-over-year to -$5.3 million; the TTM figure through Dec 2025 stood at -$7.1 million (down 1017.67% YoY), while the FY2025 annual figure was -$6.9 million, down 988.29% from the prior year.
- Change in Receivables came in at -$5.3 million for Q4 2025 at Immatics, down from -$1.5 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $6.5 million in Q3 2022 to a low of -$7.1 million in Q2 2022.
- A 5-year average of -$484373.4 and a median of -$206532.8 in 2023 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables soared 1561.87% in 2022 and tumbled 13576.12% in 2023, its largest moves.
- Immatics' Change in Receivables stood at $50334.7 in 2021, then sank by 43.25% to $28566.9 in 2022, then sank by 13576.12% to -$3.8 million in 2023, then surged by 117.88% to $688175.4 in 2024, then tumbled by 870.14% to -$5.3 million in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered -$5.3 million, -$1.5 million, and -$211676.5 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - | -5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.30 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -1.49 Mn |
| Sep 30, 2025 | -1.49 Mn |
| Jun 30, 2025 | -211,676.46 |
| Jun 30, 2025 | -211,676.46 |
| Mar 31, 2025 | -94,669.60 |
| Mar 31, 2025 | -94,669.60 |
| Dec 31, 2024 | 688,175.44 |
| Dec 31, 2024 | 688,175.44 |
| Sep 30, 2024 | -750,083.92 |
| Sep 30, 2024 | -750,083.92 |
| Jun 30, 2024 | -396,294.63 |
| Jun 30, 2024 | -396,294.63 |
| Mar 31, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | -3.85 Mn |
| Dec 31, 2023 | -3.85 Mn |
| Sep 30, 2023 | -201,389.24 |
| Sep 30, 2023 | -201,389.24 |
| Jun 30, 2023 | 595,641.64 |
| Jun 30, 2023 | 595,641.64 |
| Mar 31, 2023 | 251,161.99 |
| Mar 31, 2023 | 251,161.99 |
| Dec 31, 2022 | 28,566.93 |
| Dec 31, 2022 | 28,566.93 |
| Sep 30, 2022 | 6.50 Mn |
| Sep 30, 2022 | 6.50 Mn |
| Jun 30, 2022 | -7.12 Mn |
| Jun 30, 2022 | -7.12 Mn |
| Mar 31, 2022 | -263,749.36 |
| Mar 31, 2022 | -263,749.36 |
| Dec 31, 2021 | 50,334.72 |
| Dec 31, 2021 | 50,334.72 |
| Sep 30, 2021 | -444,591.32 |
| Sep 30, 2021 | -444,591.32 |
| Jun 30, 2021 | -367,302.79 |
| Jun 30, 2021 | -367,302.79 |
| Mar 31, 2021 | 1.46 Mn |
| Mar 31, 2021 | 1.46 Mn |
| Dec 31, 2020 | -240,842.55 |
| Dec 31, 2020 | -240,842.55 |
| Sep 30, 2020 | -726,544.04 |
| Sep 30, 2020 | -726,544.04 |
| Jun 30, 2020 | 994,618.50 |
| Jun 30, 2020 | 994,618.50 |
| Mar 31, 2020 | -411,769.26 |
| Mar 31, 2020 | -411,769.26 |
| Dec 31, 2019 | -1.10 Mn |
| Dec 31, 2019 | -1.10 Mn |
| Sep 30, 2019 | -14.27 Mn |
| Sep 30, 2019 | -14.27 Mn |